July 18, 2017

Mutations in TP53 and JAK2 Are Independent Prognostic Biomarkers in B-Cell ALL

Next-generation deep sequencing was used to determine the mutational status of hotspot regions in 340 adults and children with B-cell precursor ALL. The frequency of adult vs child mutations was significantly higher (20.2% vs 7.6%). The most commonly mutated genes were TP53, JAK2, CRLF2, PAX5, LEF1, and IL7R, respectively. Significantly lower overall survival and event-free […]

Mutations in TP53 and JAK2 Are Independent Prognostic Biomarkers in B-Cell ALL Read More »

Dabrafenib Plus Trametinib vs Dabrafenib in Metastatic BRAF V600E/K–Mutant Melanoma

Patients with previously untreated BRAF V600E/K–mutant metastatic melanoma were enrolled in this double-blinded phase III study of combination dabrafenib and trametinib (n = 211) vs dabrafenib plus placebo monotherapy (n = 212). Here, the authors here look at the efficacy and safety data following ≥36 months of follow-up. The 3-year progression-free survival was 22% in

Dabrafenib Plus Trametinib vs Dabrafenib in Metastatic BRAF V600E/K–Mutant Melanoma Read More »